Table of Contents
Chemotherapy Research and Practice
Volume 2012, Article ID 351210, 10 pages
http://dx.doi.org/10.1155/2012/351210
Review Article

Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

Division of Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New york, NY 10461, USA

Received 18 May 2012; Revised 24 July 2012; Accepted 24 July 2012

Academic Editor: Sue S. Yom

Copyright © 2012 Shaad E. Abdullah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Peréz-Soler and L. Saltz, “Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5235–5246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. E. Lacouture, M. L. Maitland, S. Segaert et al., “A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group,” Supportive Care in Cancer, vol. 18, no. 4, pp. 509–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. S. Joshi, S. Ortiz, J. N. Witherspoon et al., “Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life,” Cancer, vol. 116, no. 16, pp. 3916–3923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. S. Herbst, P. M. LoRusso, M. Purdom, and D. Ward, “Dermatologic side effects associated with gefitinib therapy: clinical experience and management,” Clinical Lung Cancer, vol. 4, no. 6, pp. 366–369, 2003. View at Google Scholar · View at Scopus
  5. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 23, p. 4811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Scope, A. L. C. Agero, S. W. Dusza et al., “Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5390–5396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. Lacouture, E. P. Mitchell, B. Piperdi et al., “Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 8, pp. 1351–1357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Potthoff, R. Hofheinz, J. C. Hassel et al., “Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion,” Annals of Oncology, vol. 22, no. 3, pp. 524–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Duvic, “EGFR inhibitor-associated acneiform folliculitis: assessment and management,” American Journal of Clinical Dermatology, vol. 9, no. 5, pp. 285–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Pérez-Soler, A. Chachoua, L. A. Hammond et al., “Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 16, pp. 3238–3247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Gatzemeier, A. Pluzanska, A. Szczesna et al., “Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1545–1552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. N. Rich, D. A. Reardon, T. Peery et al., “Phase II trial of gefitinib in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 22, pp. 133–142, 2004. View at Google Scholar
  15. B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Marshall, “Clinical implications of the mechanism of epidermal growth factor receptors inhibitors,” Cancer, vol. 107, no. 6, pp. 1207–1218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Okines, D. Cunningham, and I. Chau, “Targeting the human EGFR family in esophagogastric cancer,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 492–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. S. Herbst and D. M. Shin, “Monoclonal antibodies to target epidermal growth factor receptor-positive tumors a new paradigm for cancer therapy,” Cancer, vol. 94, no. 5, pp. 1593–1611, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Mendelsohn, “The epidermal growth factor receptor as a target for cancer therapy,” Endocrine-Related Cancer, vol. 8, no. 1, pp. 3–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. E. S. Kim, F. R. Khuri, and R. S. Herbst, “Epidermal growth factor receptor biology (IMC-C225),” Current Opinion in Oncology, vol. 13, no. 6, pp. 506–513, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Carpenter and S. Cohen, “epidermal growth factor,” Annual Review of Biochemistry, vol. 48, pp. 193–216, 1979. View at Google Scholar · View at Scopus
  24. M. Yao, T. Shuin, H. Misaki, and Y. Kubota, “Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer,” Cancer Research, vol. 48, no. 23, pp. 6753–6757, 1988. View at Google Scholar · View at Scopus
  25. B. W. Ennis, M. E. Lippman, and R. B. Dickson, “The EGF receptor system as a target for antitumor therapy,” Cancer Investigation, vol. 9, no. 5, pp. 553–562, 1991. View at Google Scholar · View at Scopus
  26. J. C. Hu, P. Sadeghi, L. C. Pinter-Brown, S. Yashar, and M. W. Chiu, “Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management,” Journal of the American Academy of Dermatology, vol. 56, no. 2, pp. 317–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. E. King Jr., R. E. Gates, C. M. Stoscheck, and L. B. Nanney, “The EGF/TGF alpha receptor in skin,” Journal of Investigative Dermatology, vol. 94, pp. 164S–170S, 1990. View at Google Scholar
  28. R. Sipples, “Common side effects of anti-EGFR therapy: acneform rash,” Seminars in Oncology Nursing, vol. 22, no. 1, pp. 28–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Guttman-Yassky, A. Mita, M. De Jonge et al., “Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib,” European Journal of Cancer, vol. 46, no. 11, pp. 2010–2019, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Kobayashi, T. J. Boggon, T. Dayaram et al., “EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 352, no. 8, pp. 786–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Parmar, C. Schumann, R. üdiger S et al., “Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity,” The Pharmacogenomics Journal. In press.
  32. K. Klinghammer, M. Knödler, A. Schmittel, V. Budach, U. Keilholz, and I. Tinhofer, “Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment,” Clinical Cancer Research, vol. 16, no. 1, pp. 304–310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. L. Huang, C. H. Yang, K. H. Yeh et al., “EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment,” Lung Cancer, vol. 64, no. 3, pp. 346–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Rudin, W. Liu, A. Desai et al., “Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1119–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. L. I. Wagner and M. E. Lacouture, “Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae,” Oncology, vol. 21, no. 11, pp. 34–36, 2007. View at Google Scholar · View at Scopus
  36. B. You, A. Brade, J. M. Magalhaes et al., “A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies,” Investigational New Drugs, vol. 29, pp. 996–1003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Rojo, E. Gracias, N. Villena et al., “Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study,” Clinical Cancer Research, vol. 16, no. 8, pp. 2474–2482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. O. Rodríguez, T. C. Rivero, R. D. C. Bahi et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Wollenberg, N. Moosmann, E. Klein, and K. Katzer, “A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition,” Experimental Dermatology, vol. 17, no. 9, pp. 790–792, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Pérez-Soler, J. P. Delord, A. Halpern et al., “HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum,” Oncologist, vol. 10, no. 5, pp. 345–356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. E. Lacouture, M. L. Maitland, S. Segaert et al., “A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group,” Supportive Care in Cancer, vol. 18, no. 4, pp. 509–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. F. S. Galimont-Collen, L. E. Vos, A. P. M. Lavrijsen, J. Ouwerkerk, and H. Gelderblom, “Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors,” European Journal of Cancer, vol. 43, no. 5, pp. 845–851, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. E. P. Mitchell, R. Perez-Soler, E. Van Cutsem, and M. E. Lacouture, “Clinical presentation and pathophysiology of EGFRI dermatologic toxicities,” Oncology, vol. 21, no. 11, pp. 4–9, 2007. View at Google Scholar · View at Scopus
  44. J. Boucher, L. Olson, and B. Piperdi, “Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors,” Clinical Journal of Oncology Nursing, vol. 15, pp. 501–508, 2011. View at Google Scholar
  45. T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture, “Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management,” Oncologist, vol. 12, no. 5, pp. 610–621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. M. E. Lacouture and S. E. Lai, “The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome,” British Journal of Dermatology, vol. 155, no. 4, pp. 852–854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Basti, “Ocular toxicities of epidermal growth factor receptor inhibitors and their management,” Cancer Nursing, vol. 30, no. 4, pp. S10–S16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Gutzmer, J. C. Becker, A. Enk et al., “Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician,” Journal of the German Society of Dermatology, vol. 9, no. 3, pp. 195–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Gridelli, P. Maione, D. Amoroso et al., “Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting,” Critical Reviews in Oncology/Hematology, vol. 66, no. 2, pp. 155–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Bernier, J. Bonner, J. B. Vermorken et al., “Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck,” Annals of Oncology, vol. 19, no. 1, pp. 142–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. E. H. Tan and A. Chan, “Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors,” Annals of Pharmacotherapy, vol. 43, no. 10, pp. 1658–1666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Jatoi, “Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash,” Supportive Cancer Therapy, vol. 4, no. 4, pp. 198–202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. V. Hirsh, “Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer,” Current Oncology, vol. 18, no. 3, pp. 126–138, 2011. View at Google Scholar · View at Scopus
  54. L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Van Cutsem, M. Peeters, S. Siena et al., “Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1658–1664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Segaert and E. Van Cutsem, “Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors,” Annals of Oncology, vol. 16, no. 9, pp. 1425–1433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Segaert, J. Tabernero, O. Chosidow et al., “The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies,” Journal of the German Society of Dermatology, vol. 3, no. 8, pp. 599–606, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. M. E. Lacouture, M. J. Anadkat, R. J. Bensadoun et al., “Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities,” Supportive Care in Cancer, vol. 19, pp. 1079–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Jatoi, K. Rowland, J. A. Sloan et al., “Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB),” Cancer, vol. 113, no. 4, pp. 847–853, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Jatoi, S. R. Dakhil, J. A. Sloan et al., “Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB),” Supportive Care in Cancer, vol. 25, article 494s, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Perez-Soler, Y. Zou, T. Li, and Y. H. Ling, “The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab,” Clinical Cancer Research, vol. 17, pp. 6766–6777, 2011. View at Google Scholar
  66. B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni, “Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies,” Clinical Cancer Research, vol. 13, no. 13, pp. 3913–3921, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. B. Klein and M. Gottfried, “Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab,” Journal of B.U.ON., vol. 12, supplement 1, pp. S127–S136, 2007. View at Google Scholar · View at Scopus
  68. F. Hong, R. D. Hansen, J. Yan et al., “β-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells,” Cancer Research, vol. 63, no. 24, pp. 9023–9031, 2003. View at Google Scholar · View at Scopus
  69. M. E. Tamayo GHC, J. B. Bautista, M. L. Flores et al., “A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC),” Journal of Clinical Oncology, vol. 28, abstract e14103, 2010, ASCO Annual Meeting Proceedings. View at Google Scholar
  70. N. H. Segal NS, P. Gada, L. M. Marsh, M. A. Gargano, and M. L. Patchen LS, “Imprime PGG improves survival in KRAS mutant colorectal cancer patients,” in European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer, 2011.
  71. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival,” The Lancet Oncology, vol. 11, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Budach, E. Bölke, and B. Homey, “Severe cutaneous reaction during radiation therapy with concurrent cetuximab,” The New England Journal of Medicine, vol. 357, no. 5, pp. 514–515, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Ang, Q. Zhang, D. Rosenthal et al., “A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC),” Journal of Clinical Oncology, vol. 29, p. 5500, 2011. View at Google Scholar
  74. I. R. Campbell and M. H. Illingworth, “Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial,” Clinical Oncology, vol. 4, no. 2, pp. 78–82, 1992. View at Google Scholar · View at Scopus
  75. I. Roy, A. Fortin, and M. Larochelle, “The impact of skin washing with water and soap during breast irradiation: a randomized study,” Radiotherapy and Oncology, vol. 58, no. 3, pp. 333–339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Salvo, E. Barnes, J. van Draanen et al., “Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature,” Current Oncology, vol. 17, no. 4, pp. 94–112, 2010. View at Google Scholar · View at Scopus
  77. R. C. Miller, D. J. Schwartz, J. A. Sloan et al., “Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4,” International Journal of Radiation Oncology Biology Physics, vol. 79, no. 5, pp. 1460–1466, 2011. View at Publisher · View at Google Scholar · View at Scopus